Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Episurf Ip-Management AB is currently prosecuting 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, reflecting a split in the oversight of the portfolio's pending matters. Additionally, the applications are being reviewed in 2 distinct art units, which suggests that the subject matter is diverse enough to fall under different USPTO technical classifications. This requires the applicant to manage two separate examination tracks simultaneously.
The busiest examiner for the portfolio is LIN, JESSICA YIFANG, who is handling 1 busiest examiner pending office action. Since there are 2 pending office actions total, the workload is shared between the 2 distinct examiners. This distribution ensures that the portfolio's advancement is not dependent on a single examiner's schedule or interpretation. However, the presence of 2 distinct art units means that the prosecution must adhere to the specific procedural requirements of different examination groups.
The 2 pending office actions in the Biotechnology & Pharmaceuticals sector indicate an ongoing effort to secure intellectual property rights. Because the examiners are working in separate art units, the company is likely encountering different sets of prior art. Successfully navigating these separate paths requires a consistent legal strategy that can be adapted to the unique technical focus of each unit involved in the prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIN, JESSICA YIFANG | 1 | 81.3% | +12.5% |
| BATES, DAVID W | 1 | 76.4% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18098985 | CREATION OF A HEALTHIER PATELLOFEMORAL JOINT | LIN, JESSICA YIFANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17952439 | STANDARDIZED IMPLANT WITH INDIVIDUALIZED GUIDE TOOL | BATES, DAVID W | 34d |
| 18098985 | CREATION OF A HEALTHIER PATELLOFEMORAL JOINT | LIN, JESSICA YIFANG | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| 3799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18098985 | CREATION OF A HEALTHIER PATELLOFEMORAL JOINT | LIN, JESSICA YIFANG | 1687 | §103 | Final Rejection | — | Pending | Jan 19, 2023 |
| 17952439 | STANDARDIZED IMPLANT WITH INDIVIDUALIZED GUIDE TOOL | BATES, DAVID W | 3799 | §103 | Final Rejection | 34d | Pending | Sep 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpisurf Ip-Management AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jessica Yifang Lin has the most, with 1 of Episurf Ip-Management AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
